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ABSTRACT 
Epidemiological studies have revealed a complex association between human genetic 
variance and cancer risk. Quantitative biological modeling based on experimental data 
can play a critical role in interpreting the impact of genetic variation on biochemical 
pathways relevant to cancer development and progression. Defects in human DNA base 
excision repair (BER) proteins can reduce cellular tolerance to oxidative DNA base 
damage caused by endogenous and exogenous sources, such as exposure to toxins and 
ionizing radiation. If not repaired, DNA base damage leads to cell dysfunction and 
mutagenesis, consequently leading to cancer, disease, and aging. Population screens have 
identified numerous single nucleotide polymorphism (SNP) variants in many BER 
proteins, and some have been purified and found to exhibit mild kinetic defects. 
Epidemiological studies have led to conflicting conclusions on the association between 
SNP variants in BER proteins and cancer risk. Using experimental data for cellular 
concentration and the kinetics of normal and variant BER proteins, we apply a previously 
developed and tested human BER pathway model to (i) estimate the impact of mild 
variants on BER of abasic sites and 8-oxoguanine, a prominent oxidative DNA base 
modification, (ii) identify ranges of variation associated with substantial BER capacity 
loss, and (iii) reveal non-intuitive consequences of multiple simultaneous variants. Our 
findings support previous work suggesting that mild BER variants have a minimal effect 
on pathway capacity, while more severe defects and simultaneous variation in several 
BER proteins can lead to inefficient repair and potentially deleterious consequences of 
cellular damage.
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INTRODUCTION 
 
DNA is continuously being damaged by endogenous sources, such as oxidative base 
modification resulting from reactive oxygen species (ROS) attack (reviewed in (1)). ROS 
are formed as metabolites during normal cellular respiration, with increased levels of 
ROS, as well as increased DNA base damage, associated with ischemia (2, 3), hyperoxia 
in human lung cells (4), human artherosclerotic plaques (5), and chronic inflammation in 
ulcerative colitis patients (6). ROS are also formed as secondary damaging agents as a 
result of exposure to toxins and ionizing radiation (e.g., sunlight, environmental IR). 
DNA base damage can lead to genotoxicity, replication stalling, apoptosis, and 
mutagenesis, with physiological consequences including disease, aging, and cancer, as 
reviewed in (7). Modified bases not only affect transcriptional integrity and replication, 
but also DNA-protein binding (8, 9). Consequently, oxidative DNA base damage is 
normally removed and repaired by the efficient base excision repair (BER) pathway 
system of prokaryotic and eukaryotic cells, reviewed in (1, 10, 11). 
 Population screens have identified extensive genetic variation, in particular single 
nucleotide polymorphisms (SNPs), altering the primary amino acid sequence of DNA 
base excision repair proteins (e.g., (12)). This genetic variation has been found in some 
instances to diminish the stability or efficiency of the encoded repair protein, reducing its 
kinetic effectiveness (13-15). Furthermore, sequence variants with potential kinetic 
impact have been predicted computationally (16). Splice variants of repair genes have 
also been identified in cancerous cells, some of which may lead to a dominant negative 
protein form with reduced repair efficiency (17, 18). 
 Non-functional DNA repair alleles, such as BRCA1/2 for breast cancer (19) and 
MSH2 and MLH1 for hereditary non-polyposis colorectal cancer (20), are “cancer genes” 
strongly linked to increased cancer risk.  However, “cancer genes” account for only about 
5% of known cancer cases (21, 22).  Consequently, reduced function repair protein 
variants may be exposure-dependent susceptibility alleles responsible for the majority of 
observed increased cancer risk associated with family history (23) as well as sporadic 
cancer incidence. Epidemiological evidence for a correlation of BER gene variants with 
cancer risk is abundant, albeit conflicting, as reviewed in (24, 25). Nonetheless, extracts 
from cells of head and neck cancer patients (26) and smokers with lung cancer have been 
found to exhibit reduced DNA repair efficiency (27) associated with the presence of BER 
protein variants and defective BER protein activity respectively.  
 The BER pathway system includes proteins with multiple enzymatic activities, 
cooperativity, and compensatory sub-pathways. This complexity makes it difficult to 
intuitively estimate how variation in a single repair protein will change a cell’s overall 
ability to tolerate DNA base damage. Moreover, there is a high likelihood that individuals 
will possess multiple variations, which in combination can further increase or reduce 
pathway capacity. Consequently, we apply a mathematical model of human BER that 
integrates biological knowledge of enzyme mechanisms and biochemical data on enzyme 
kinetics and protein concentration obtained from the literature. This model has been used 
to interpret published data from in vitro pathway reconstitution and cell extracts to 
evaluate mechanistic hypotheses of enzyme cooperativity and coordination and predict 
the relative significance of the BER sub-pathways (28). Notably, the model recently 
predicted that under normal conditions, background oxidative DNA base damage level is 
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at the low end of the widely varying published measurements, i.e., up to hundreds of 
lesions per cell, and that the background level is relatively stable to small changes in 
enzyme kinetics (29). In the context of the normally robust operation of BER, we applied 
the model based on published experimental data to: (i) estimate the potential impact if 
any of the previously characterized BER variant proteins, (ii) identify the magnitude of 
changes in individual protein kinetics and concentration required to observe a substantial 
difference in overall BER kinetics and capacity, and (iii) use the model to predict the 
effect of simultaneous variation in multiple repair proteins on total BER kinetics. 
 
MODEL & METHODS 
 
BER Pathway Model Structure.  The comprehensive BER pathway model is based on 
current biological knowledge, illustrated in Fig. 1. The BER pathway in the nucleus is 
initiated by a lesion-specific DNA glycosylase, which recognizes and removes damaged 
bases (30). For example, 8-oxoguanine (8-oxoG; y1 in Fig. 1) is removed by 8-oxoG 
DNA glycosylase (Ogg1; e1). Some DNA glycosylases (including Ogg1) also exhibit an 
AP lyase activity, incising 3’ to the abasic (AP) residue, leading to a subpathway 
(Pathway A) in which the phosphodiesterase activity of human AP endonuclease (Ape1; 
e2) removes the 3’ block (y10) (31, 32). In most cases, “short-patch” BER (Pathway B) 
occurs (33), where Ape1 incises 5’ to the lesion (34). The resultant 5’-deoxyribose 
phosphate (dRp; y4) group is removed by the dRp lyase activity of DNA polymerase β 
(Polβ; e3), which then executes single base replacement at the gapped site (y5 or y11). In 
our model, the Polβ-catalyzed activities may occur in either order (thus the fork in 
Pathway B). An alternative “long-patch” BER pathway (Pathway C) exists in which gap-
filling of 2-7 nucleotides is performed by Polδ (e4) or possibly Polε (excluded from our 
model due to a lack of kinetic data) in complex with PCNA followed by flap excision by 
Fen1 (e5) and subsequent ligation (35). The final step in all sub-pathways is performed by 
DNA Ligase 1 (Lig1; e6), or Lig3 (e7) stabilized in complex with Xrcc1 (36). Lig1 and 
Lig3/Xrcc1 activities appear largely interchangeable (37), though a few recent results 
indicate that Lig1 may be more significant for long-patch repair (38). 
 Model Assumptions.  In general, reactions in the model are modeled using 
Michaelis-Menten enzyme kinetics, with kcat and KM parameters defining a reaction 
velocity (vi in Fig. 1). This implicitly assumes homogeneity and deterministic, continuous 
reaction kinetics, which are justified by the high concentration of repair proteins as 
discussed in (28). If Michaelis-Menten assumptions hold for a biochemical system, then 
kcat is interpreted as the catalytic turnover rate of the enzyme (its “activity”), and KM is a 
function of the affinity of the enzyme for the substrate. 
 To account for experimental measurement of 5 to 10-fold reduced diffusion 
velocities in the crowded cell nucleus (39), KM of all reactions are increased 10-fold (due 
to the reduction in collision probability). The model includes experimentally measured 
protein cooperativity by kcat increases as in previous modeling (28, 29), as well as 
including coordination of consecutive single enzyme activities (such as Polβ and the 
dual-function DNA glycosylases, e.g., Ogg1) by modeling the second step as a first-order 
reaction, as described in (28). We also assume no product inhibition for individuals under 
normal conditions in the pathway, as suggested by observations (32, 40). We do not 
however include the potential role of Xrcc1 as a mediator of a multiprotein coordination 
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complex (41), as the contribution of Xrcc1 to such a complex forming and any 
consequent enhancement of BER kinetics are unclear (42, 43). In addition, many of the 
potential coordinative effects are already in the model. Table 1 shows kinetic parameters 
used in the model, including rate enhancements due to cooperativity. 
 Model Protein Concentrations.  Table 2 shows BER protein concentrations 
determined from published data calculated by assuming the number of proteins measured 
per cell are homogenously distributed in a nucleus with a diameter of 5 μm, as described 
in (28, 29). Because of the limited data currently available, these protein levels were 
drawn from various cell lines. Where multiple measurements were available, a 
conservative assumption was used, since some are from tumor cell lines, which have 
been measured to have higher protein expression levels than normal cells (76). 
Furthermore, Ape1 (79-80) and DNA glycosylases, such as Ogg1 (81), may be 
distributed in both the nucleus and other cell compartments (i.e., cytosol and 
mitochondria). In our analysis, we neglect the contribution to overall cellular DNA 
damage of the oxidative damage in mitochondria, which is repaired equally or more 
efficiently than nuclear DNA and does not occur at levels measurable in whole cell 
assays (82-84). Consequently, protein concentrations in Table 2 do not include Ogg1 and 
Ape1 localized to mitochondria (74, 81, 85). We have found in our analysis of the 
sensitivity of our results to protein concentration that it closely follows that of sensitivity 
to kcat, which is published here (results not shown; similar results were also found in our 
previous work on estimating steady-state BER capacity (29)). This is expected from the 
mathematical form of the Michaelis-Menten equations used to model most of the BER 
pathway. 
 Solution of Model Equations.  The mathematical structure of the model is 
identical to that in (29). Differential equations were solved using the ‘ode15s’ stiff solver 
of MATLAB R14 using parameters from Tables 1 and 2, adjusted by the analysis 
described below. Steady-state reactant levels were the equilibrium point found by 
simulating the differential equations on a time scale of 24 hours and then setting 
equations for repair intermediate concentrations equal to zero and using the nonlinear 
least squares MATLAB routine ‘fsolve’ to solve the resulting algebraic system (results 
not shown). 
 
RESULTS 
 
Simulation of 8-oxoguanine (8-oxoG) levels as an estimate for oxidative DNA base 
repair capacity.  We focus on the repair of 8-oxoguanine (8-oxoG) initiated by Ogg1, 
which includes the full set of pathway steps in Fig. 1. This is motivated by the large 
amount of data from experimental sources for the kinetics of wild type and polymorphic 
forms of Ogg1 (28), as well as cellular and physiological levels of 8-oxoG (e.g., (86); 
also reviewed in (29)). 8-oxoG is frequently used as marker for oxidative DNA damage 
associated with disease consequences (87). As further data accumulate for the kinetics 
and cellular abundance of other DNA glycosylases (88), we can extend our analysis in 
the future using the approach described herein. In our studies, we assume that the 
contribution of NEIL1/2 enzymes recently found to have 8-oxoG DNA glycosylase 
activity (89) are quantitatively insignificant as compared to Ogg1; recent studies have 
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suggested that their biological role may be primarily for specialized cases, such as 
damage within bubble DNA structures (90, 91). 
 We account for the production of other base lesions in our modeling by including 
an additional damage load of abasic (apurinic/apyrimidinic; AP) sites, comprising the 
products of other DNA glycosylases, as well as spontaneous hydrolysis and base loss, the 
majority of which result in apurinic sites (92). Overall, we predict the combined numbers 
of original lesions and repair intermediates, which are a significant component of 
observed lesions (93) and may be highly genotoxic and mutagenic themselves (94, 95). 
 Estimated impact of mild protein variants found in the population on BER 
kinetics and capacity.  If a protein variant is found to affect the kinetics of a BER 
reaction, then its impact on the overall pathway is estimated by modifying the appropriate 
kcat and KM parameters for that reaction in the comprehensive BER system model. 
Published data are available for the kinetics of some BER proteins coded by sequence 
variants identified in population screens. Ape1 variants were characterized with AP 
endonuclease efficiencies from 35-110% of wild type (13). These are calculated based on 
the amount of repair of an initial lesion concentration over a fixed period of time, and 
they may be interpreted as being equivalent to the catalytic rate (kcat) of Ape1. The 
commonly found Ogg1 polymorphism Ser326Cys has a reported kcat 63% of wild type 
(15), and other Ogg1 variants were found to have a kcat 44% (Arg154His) and 85% 
(Arg36Gln) of wild type (14). In the case of Polβ, one quantitatively characterized allelic 
variant is a dominant negative inhibitor of wild type activity (17). Based on the measured 
equilibrium binding affinity (KD) of the variant with the Polβ substrate and potential cell 
concentration, the effective KM for Polβ gap-filling reaction is increased 3 to 5-fold 
(calculated based on competitive inhibition in the Michaelis-Menten model). The 
estimated impact of protein variants in these ranges of variation are shown in Fig. 2, 
where we have simulated the effect of Ape1 with 10% of normal kcat (the highest amount 
at which any difference could be observed), Ogg1 with 50% of normal kcat, and Polβ with 
a 5-fold increase in KM. 
 Fig. 2 illustrates two possible kinds of impact on the BER pathway: the capacity 
of BER to tolerate a constant rate of base lesion formation (8-oxoG and AP site formation 
combined), and the kinetics of BER repairing an instantaneous pulse of oxidative DNA 
damage (also consisting of both 8-oxoG and AP site lesions). Such a pulse simulates 
acute exposure: for example, a dose of radiation therapy, increased metabolism during 
intense exercise, or acute inflammation during an infection. We consider repair of 
transient damage pulses in the context of continuing background base lesion formation. 
Base lesion formation rates (2,000 8-oxoG/cell/day and 20,000 AP sites/cell/day) are 
based on experimental data for normal background rates of formation (92, 96, 97). They 
are adjusted upwards to reflect (i) increased 8-oxoG corresponding to exercise and other 
variations in metabolism (98) and (ii) AP sites produced by the action of additional DNA 
glycosylases processing other base lesions. Damage “clearance” is defined as the time at 
which the background steady state level of lesions corresponding to the constant damage 
formation rate is restored. Notably, as Fig. 2 shows, 8-oxoG repair rate is more sensitive 
to small changes in protein kinetics than the steady state repair capacity. 
 Table 3 summarizes the impact on BER capacity (steady state number of lesions 
per cell upon exposure to the formation of 2,000 8-oxoG and 20,000 AP sites/cell/day) 
and BER kinetics (time to clear 10,000 8-oxoG and 100,000 AP sites) of each protein in 
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the pathway with 10% and 50% of their normal (Table 1) kcat. Results are given for each 
of the activities of multiple-function proteins separately. Data are provided as a 
percentage increase in steady state damage and clearance time with respect to normal 
protein kinetics. Table entries of “0%” represent a change less than 0.01% (results not 
shown). Notably, because of the dominance of Pathway B for our model of 8-oxoG 
repair, assuming normal Polβ function, Pathway C proteins, Polδ and Fen1, will have 
negligible impact on kinetics, as was found in our previous modeling analysis (28). 
 Sensitivity analysis of BER pathway capacity to hypothetical protein 
variants.  In Fig. 2, curves showing an increased lesion burden and clearance time as a 
result of increased damaged load show a quantitatively small difference for mild kinetic 
variants of BER proteins. This suggests that the BER pathway is apparently robust to 
mild kinetic variation. Accordingly, we explored a wider range of protein kinetic 
parameters to identify levels at which variants may have a qualitatively observable 
impact on BER pathway capacity, as shown in Fig. 3 for kcat and KM (modified relative to 
the normal values in Table 1; not shown are variants for BER reactions that were found to 
have no effect on steady state damaged base levels, e.g., Fen1 kcat and KM). While the 
analysis in Fig. 3 is specifically for steady state damage levels given physiologically 
relevant levels of 8-oxoG and AP site formation, it qualitatively reflects the general 
sensitivity of the BER pathway to its individual components. Regions on the plots in Fig. 
3 that show a rapidly changing curve represent parameter values for which BER capacity 
is highly sensitive and less robust to increases in damage level. Regions for which no 
curve is plotted at all represent parameter ranges of BER pathway kinetics that preclude a 
steady state equilibrium point. For these hypothetical kinetic variants, the BER pathway 
breaks down, with lesions and repair intermediates accumulating uncontrollably. For 
normal BER reaction kinetics, this breaking point is approximately 125,000 8-
oxoG/cell/day (29), a level that seems physiologically unrealistic. By comparison, in cell 
culture, 8-oxoG formation was measured at 0.01/106 bases per Gy (99), and 8-oxoG 
levels on the order of 100/106 have been measured in naked DNA exposed to highly 
oxidative agents or >5 Gy radiation (100). But, for some modeled changes in the kcat and 
KM of Ogg1, Ape1, Polβ, and Lig1, it can be on the order of 104 8-oxoG/cell/day (data 
not shown) or less – for example, where the curves are not shown on Fig. 3. Such variants 
will result in a BER pathway incapable of tolerating even normal damage formation rates 
(i.e., 103 8-oxoG/cell/day and 104 AP sites/cell/day) without accumulating unrepaired 
lesions. 
 Fig. 3 shows the sensitivity of repair capacity to changes in only Lig1 kinetic 
efficiency. The concentration and kinetics of Lig3 were assumed to be equivalent to those 
of Lig1. Consequently, simulated predictions for Lig3 are identical to those for Lig1, 
demonstrating redundancy in the DNA ligation step of the repair pathway. This agrees 
partially with experimental results in (37), which do suggest that in some cases one DNA 
ligase may be preferred to another. Due to the redundant role of Lig1 and Lig3 in our 
model, simulated data predict that BER capacity is sensitive to reduction in Lig1 kinetics 
to a certain point, after which further reduction no longer affects the pathway, as shown 
in Fig. 3. 
 Observation of unexpected synergies for hypothetical multiple protein 
variants in the BER pathway.  In some cases, the complexity of individual protein 
kinetics within the context of the whole BER pathway leads to unexpected synergistic 
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variation. To illustrate this, we estimate the consequence of simultaneous variation of 
Ape1 5’-incision activity and Polβ gap-filling and 5’dRp lyase catalytic activities (kcat) on 
overall BER dynamics for the repair of a transient pulse of DNA damage, assuming that 
the Polβ rate enhancement by Ape1 is unaffected. In the steady state analysis (not 
shown), there is only a 3.75 to 4 lesion/cell difference (including repair intermediates) 
between Polβ variants with 200-fold reduced kcat and 10-fold reduced kcat (assuming 
constant rates of formation of 2,000 8-oxoG/cell/day and 20,000 AP sites/cell/day), with 
the exception of the situation with a 1000-fold Ape1 kcat reduction, in which case the 
number of steady state lesions differ by 27 per cell. This contrasts with the findings 
shown in Fig. 4 for transient repair dynamics. The time to fully clear a pulse of 8-oxoG 
and abasic lesions and repair intermediates for the Polβ-inefficient pathway is at its 
maximum when Ape1 kcat is 70% of normal. As Fig. 4B shows, this point of respective 
Ape1 and Polb activity modification is a peak (darkest region). Repair efficiency 
improves (more lightly shaded regions of Fig. 4B) as Ape1 kinetics either increase or 
decrease, and the overall system shows less sensitivity to reduced Polβ kinetics. 
 (par. break) Based on a study of the estimated levels of BER intermediates during 
the simulation, it appears that at that particular critical level of Ape1, there is a shifting of 
repair to Pathways A and C, which are slower than Pathway B – and sites being repaired 
through Pathway A are particularly sensitive to Polβ kinetics following the first steps. 
Consequently, there is a persistence of repair intermediates and prolongation of the time 
to reach the normal steady state background. As this model analysis demonstrates, the 
complexity of multiple sub-pathways in the BER pathway can be a mechanism for 
unexpected synergies between protein variants, which are not merely additive results of 
reduced kinetic rates. 
  
DISCUSSION 
 
There have been numerous investigations of potential correlations between BER gene 
variants (e.g., SNPs, truncations, frameshifts) with levels of biomarkers, including DNA 
damage and mitotic delay, prevalence in tumor cells, and increased cancer susceptibility. 
To date, many of these studies have been inconclusive or contradictory. For instance, the 
commonly found Ser326Cys variant of Ogg1 has been found to be correlated 
epidemiologically with increased cancer risk, increased measurements of cellular DNA 
base damage, and reduced base repair kinetics in several studies and assays (101-108), 
while null or statistically insignificant correlations have been found in others (102, 109-
112); also a recent extensive review (113). Applying a previously developed and tested 
comprehensive BER pathway model integrating reaction mechanisms and parameters 
obtained from published experimental data, we estimate that Ogg1 base excision kcat 
reduced by 50%, comparable to that of the Ogg1 Ser326Cys polymorphism (15), results 
in a decrease of approximately 5-10% in BER capacity, as defined by the steady state 
number of lesions per cell for a wide range of constant damage formation rates (as shown 
in Fig. 2). The transient kinetics of repairing a pulse of damage are somewhat more 
sensitive to mild kinetic variants, but effects are still minimal. 
 Overall, our modeling supports a complex role for genetics in tolerating exposure 
to genotoxic stresses in determining DNA base damage tolerance and cancer risk. Under 
normal and increased damage loads and rates (simulated based on experimental 
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measurements) results favor the null or marginal experimental findings for the impact of 
Ogg1 Ser326Cys on cellular tolerance of oxidative damage and cancer susceptibility. 
Furthermore, Ape1 population variants characterized in (13) are estimated by our 
modeling to have a negligible effect on BER kinetics and capacity. These results are 
supported by a null finding for cancer susceptibility with the Ape1 variant Asp146Glu in 
pooled studies (108). 
Our analysis (Fig. 3) reveals that further increases in individual repair protein 
kinetics have a minor effect on overall BER pathway kinetics, as suggested by the long 
evolutionary history of BER, conserved to a relatively high degree from E. coli through 
human cells (7). Of all its steps, the BER pathway is most sensitive to decreases in Ogg1 
base excision, Ape1 5’-incision of the abasic site, and Polβ gap-filling and 5’-dRp lyase 
reaction kinetics, with limited compensated sensitivity to DNA ligase activity. The high 
sensitivity to Ogg1 kinetics is supported by evidence that allelic loss (which reduces 
Ogg1 concentration and reaction velocity) is prevalent in tumor cells with reduced 8-
oxoG repair activity (102, 109, 114, 115). Furthermore, while there is little evidence for 
Polβ variants in cells of normal tissues in the human population, several variants with 
diminished activity have been found in tumor cell lines and are associated with reduced 
overall BER pathway capacity and a Polβ mutator phenotype, in accord with estimates 
presented here (17, 18, 116-121). This suggests a potentially significant role for inherited 
Polβ variants in increasing cellular susceptibility to DNA base damage and cancer risk, 
suggesting targets for further epidemiological studies. 
While the assumption of redundant Lig1 and Lig3 activities results in a modeling 
prediction of some compensation for the case of variants, there is still notable sensitivity 
to kinetics that would be exacerbated if activities are not completely overlapping. A Lig1 
Arg771Trp variant has been characterized in an immunodeficient patient, with cell 
cultures demonstrating hypersensitivity to DNA damaging agents and impaired BER 
activity with 3-5% Lig1 kinetics (122), and a noncoding variant of Lig3 has been 
associated with increased esophageal cancer risk (123). Also, Lig3 activity requires 
Xrcc1, and there are reports associating Xrcc1 variants with increased cancer 
susceptibility (103, 123-127). However, other studies indicate null or statistically 
marginal results for Xrcc1 variants, highlighting the complexity of variant protein roles in 
the BER pathway (128-130). 
 While the association of most proteins involved in oxidative DNA base damage 
repair with cancer remains a controversial question, there is recent evidence of a direct 
link between protein sequence of MYH (the DNA glycosylase that removes a 
mismatched adenine across from the 8-oxoguanine lesion) and colorectal cancer (131-
133), reviewed in (134). There is also some evidence that MYH variants associated with 
increased cancer risk and polyposis have reduced catalytic efficiency, but published 
studies have been on human MYH sequence variants generated by site-directed 
mutagenesis not found in the population (135) or mutants of the E. coli homolog 
corresponding to the population variants (136). As further enzymatic data are obtained 
for MYH activity, our comprehensive BER system model can be extended to include 
MYH along with Ogg1 and other DNA glycosylases, allowing for estimation of variant 
impact on the whole pathway. 
 In the post-genome era, there has been tremendous investment in the search for 
genetic variants in the population related to increased cancer risk and chemoresistance, 
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particularly SNPs (137). The relative prevalence of SNPs in the population suggests that 
many are low-penetrance alleles, which will reduce the efficiency of biological pathways 
without eliminating their function entirely. As this study shows, biochemically modeling 
the impact of variants reveals complex behavior and pathway sensitivity, and can provide 
insight to interpret incomplete and contradictory results obtained from both epidemiology 
and laboratory experiments. Progress in understanding how complex genotypes can 
predict the response to endogenous background and exogenous environmental exposure 
to DNA damaging stresses will allow an individualized, predictive approach to 
interpreting the medical significance of  DNA damage quantification (138), identify 
chemoprevention strategies for individuals with known susceptibility factors (139, 140), 
and unveil mechanisms of chemoresistance (141) to therapeutics. In general, the analysis 
presented here underscores the critical role of quantitative biological system modeling 
and experiments will play in the long-term goal of the post-genomic era, effectively 
interpreting complex genetic studies and translating their findings to benefit human 
health. 
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Figure 1. Schematic of the human BER pathway model, described in the main text, 
showing substrates and intermediates (y), enzymes (e), and reactions (v). (*Abasic sites 
can be formed directly, y30, or as intermediates of a bifunctional DNA glycosylase, e.g. 
Ogg1, y2.) 
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Figure 2. Sensitivity of 8-oxoG BER capacity and kinetics to mild kinetic defects in 
Ogg1 (50% of normal kcat), Ape1 (10% of kcat), and Polβ (5-fold increased KM). (A) Total 
number of 8-oxoG, abasic, and repair intermediate bases per cell given increasing 8-oxoG 
rates of formation (assuming simultaneous production of an additional 20,000 AP 
sites/cell/day). (B) Time required to clear an instantaneous pulse of 100,000 AP sites/cell 
and an increasing number of 8-oxoG lesions/cell and restore damage to the background 
steady state level for continuous formation of 2,000 8-oxoG/cell/day and 20,000 AP 
sites/cell/day. Simulated data for the pathway with normal kinetics and with a 10% kcat 
Ape1 variant are nearly overlapping. 
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Figure 3. Sensitivity over a broad range of kcat (A) and KM (B) of enzymatic activities in 
BER (Ogg1 excision of 8-oxoG, Ape1 nicking at the 5’ end, Polβ gap-filling and 5’-dRp 
lyase reactions, Polδ gap-filling, and the ligase activity of Lig1. Changes in kinetic 
parameters are fractions and multiples of the values for those reactions in Table 1 (with 
all KM increased 10-fold as described in the text). The steady state total number of 8-
oxoG, AP sites, and repair intermediates is calculated based on a constant total damage 
formation rate of 2,000 8-oxoG lesions/cell/day and 20,000 AP sites/cell/day. The plot is 
truncated at the point where a continued KM increase results in no physically possible 
steady state. 
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Figure 4. Simulation of the effect of varying Ape1 and Polb kcat simultaneously on the 
time required to clear 10,000 8-oxoG sites and 100,000 AP sites, with a constant 
background damage formation rate of 2000 8-oxoG/cell/day and 20,000 AP 
sites/cell/day. (A) Clearance time for varying Ape1 kcat (multiple of normal parameter 
value in Table 1) for fractions of normal Polβ kcat. (B) Contour plot of clearance time for 
simultaneous changes (log ratio to normal kcat) in Ape1 and Polβ; darker regions 
correspond to higher clearance times. 
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Table 1 Normal BER Protein Kinetics 
 
Reactions 
(vi) 
kcat 
(s-1) ‡ 
KM  
(nM) ‡ 
References Rate Enhancements References 
1 0.0052 121.5 (14, 15, 32, 44-46) 10x decr. KM (Ape1); 
8x incr. kcat (Ape1; 
posttranslational 
modifications) 
(32, 47) 
2 3.2028 34.7 (32, 48-55) --- --- 
3, 6* 0.817 210 (56-59) --- --- 
4*, 5 0.075 500 (60) 6x incr. kcat (Ape1) (61, 62) 
7, 10, 14, 
16-18† 
0.0213 56.7 (56, 63, 64) 4x incr. kcat (PCNA, 
RpA) 
(64, 65) 
8, 15 0.6 100 (66-68) (Rate in presence of 
PCNA) 
--- 
9 0.1335 39 (59, 69) 2x incr. kcat (Ape1) (70) 
11 0.000887 7.2 (32) 2.5x incr. kcat (Ape1; 
posttranslational 
modification) 
(47, 71) 
12 0.0608 169 (49, 72, 73) --- --- 
 
* Assuming pathway coordination, this reaction is first order with a rate of kcat. 
† Lig3 kinetics assumed equal to those for Lig1 kinetics (37). 
‡ Where multiple sources are used in the literature, the median is used to avoid excessive 
influence by outliers.
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Table 2 BER Protein Concentrations 
 
Protein Concentration 
(nM) 
References 
Ogg1 406 (46, 74) 
Ape1 2000 (72, 74, 75) 
Polβ 419 (76, 77) 
Polδ 600 * 
Fen1 450 * 
Lig1 254 (78) † 
Lig3 254 ‡ 
 
* In absence of data, assumed based on concentration of other nuclear proteins. 
† Also, A. E. Tomkinson, personal communication. 
‡ Assumed equal to Lig1 (37). 
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Table 3 Predicted Impact of Protein Kinetic Variants on Background Damage Levels and 
Time to Clear Lesions (% of wild type)* 
 
Protein Activity  10% kcat 50% kcat 
 (vi)  Damage Time Damage Time 
Ogg1 1 base excision 29% 341% 3% 9% 
Ape1 2 5'-incision 2% 1% 0% 0% 
Polβ 3, 6 gap-filling 13% 7% 4% 2% 
Polβ 4, 5 5'-dRp lyase 32% 56% 4% 1% 
Lig1† 7, 10, 14, 16-18  53% 90% 21% 34% 
Polδ 8, 15  1% 0% 0% 0% 
Fen1 9  0% 0% 0% 0% 
Ogg1 11 AP lyase 0% 0% 0% 0% 
Ape1 12 3'-dRp lyase 0% 0% 0% 0% 
 
* Steady state number of lesions per cell is based on 2,000 8-oxoG and 20,000 AP 
sites/cell/day; time to clear is calculated for10,000 8-oxoG and 100,000 AP sites/cell. 
† Based on model assumptions, Lig3 will have the same results. 
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